Company & Sponsor Intelligence
Alnylam Pharmaceuticals
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting1
Completed0
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT07636811A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →